Ann: Quarterly Activities/Appendix 4C Cash Flow Report, page-34

Was expected to be the case with guidance from the company it was going to be lower. However, the optimist take is that half year revenue from the two products is $1.2Million.

Covid19 period sales of product at its peak was $2.2Million annually (including Covidx which accounted for $1.7Million). That same year the revenue was $9.5Million.

Which shows over the last 3 years - remained steady on services income (some fluctuations), but a baseline each year to work off. They have increased their product sales (projected on a rolling annual basis to $2.4Million if it remains the same) which is an increase on both previous years but on their peak of $200K.

Mr Market might be seeing a longer time frame for the kind of revenue they want to see. We haven't seen a full flu season with both products in market.

Dont get me wrong, i know the market wants to see 10's of millions in sales here - i believe that will come. When? who knows.

CLIA waiver would be a big trigger point to this so hopefully that occurs promptly next year.